Qiagen (QGEN) Jefferies London Healthcare Conference 2025 summary

Financial performance and guidance

• Achieved consistent core growth of 6–7% in the first three quarters despite challenging macro conditions.

• Sample preparation business accelerated to 3% growth ahead of major instrumentation launches.

• Guidance for Q4 and next year remains conservative due to ongoing U.S. funding uncertainties and academic market softness.

• Operating margin expected to end at 29.5%, with midterm expansion targeted above 31% by 2028, possibly earlier.

• Margin headwinds include acquisition dilution, FX, and tariffs, but operational improvements and product mix are expected to offset these.

Strategic initiatives and operational improvements

• Focus on five growth drivers, with all delivering well, especially sample prep and digital channels.

• Cost-out programs target gross margin via better QIAstat production utilization and higher-margin product growth.

• Digital channel revenue is at 60%, with a goal to reach 75% through embedded digital workflows.

• R&D investment to remain around 9% of revenues, with further SG&A efficiencies expected.

Product innovation and launches

• Three major sample prep instruments launching: QIAsprint (high throughput), QIAsymphony Connect (workflow integration), and QIAmini (affordable automation).

• New launches expected to drive both instrument sales and consumable pull-through, with impact seen in the second half of next year.

• Menu expansion for QIAstat-Dx in GI, meningitis, blood culture, and UTI to support U.S. and global growth.